Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Residual cancer cells in the bowel wall  after chemoradiation for rectal cancer

A study in February's issue of the Diseases of the Colon & Rectum examines the distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer.

News image

The standard treatment for locally advanced rectal cancer is preoperative chemoradiation and total mesorectal excision.

After surgery, tumors are classified according to the depth of tumor invasion, nodal involvement, and tumor regression grade.

These staging systems do not provide information about the distribution of residual cancer cells within the bowel wall.

Dr Marjun Duldulao and colleagues commented determined the distribution of residual cancer cells in each layer of the bowel wall in rectal cancer specimens.

The research team assessed that it was a secondary analysis of data from a prospective phase II study.

The researchers performed the study in a multi-institutional setting.

The team of doctors included 153 patients with stage II or stage III rectal cancer.

Patients were treated with chemoradiation and surgery.

42 of 153 patients had complete response in the bowel wall
Diseases of the Colon & Rectum

The doctors examined that the surgical specimen tumor tissue was analyzed, and the distribution of residual cancer cells in each layer of the bowel wall was determined.

Statistical analysis was used to examine the correlation of residual cancer cells in each layer of the bowel wall with the clinical/pathologic stage, and tumor regression grade.

The research team reported that 42 of 153 patients had complete response in the bowel wall.

Of the remaining 111 patients who had residual cancer cells, 5 were ypTis, 12 were ypT1, 41  were ypT2, 50  were ypT3, and 3 were ypT4.

Of the 94 patients with ypT2-4 tumors, 12 had cancer cells in the mucosa, and 53 had cancer cells in the submucosa, and 92 had cancer cells in the muscularis propria.

The doctors noted that pretreatment cT correlated with the distribution of residual cancer cells.

Tumor regression grade was not associated with the distribution of residual cancer cells after chemoradiation.

The researchers assessed that patients received different chemotherapy regimens.

Dr Marjun's team concluded, "Residual cancer cells in rectal cancer specimens after chemoradiation are preferentially located close to the invasive front."

"This should be considered when designing strategies to diagnose complete pathologic response and when investigating the mechanisms of tumor resistance to chemoradiation."

Dis Colon Rectum 2013: 56(2): 142-149
30 January 2013

Go to top of page Email this page Email this page to a colleague

 04 May 2015

Advanced search
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Menarche and NAFLD
 04 May 2015 
Endoscope storage and microbial colonization
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Hypnotherapy for IBS
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 08 April 2015 
Nonceliac gluten sensitivity
 07 April 2015 
Treatment of Hep C virus
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Endoscopic managements of GI bleeds
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 06 April 2015 
Treatment for rectal cancer
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us